Nizatidine: Difference between revisions
m Popups-assisted disambiguation from Eli Lilly to Eli Lilly and Company |
m UK -> article United Kingdom - and/or general fixes using AWB |
||
| Line 32: | Line 32: | ||
|- |
|- |
||
| bgcolor="#eeeeee" | [[Regulation of therapeutic goods|Legal status]] |
| bgcolor="#eeeeee" | [[Regulation of therapeutic goods|Legal status]] |
||
| bgcolor="#ddeeff" | Schedule 4 ([[Australia]])<br>POM ([[UK]]) |
| bgcolor="#ddeeff" | Schedule 4 ([[Australia]])<br>POM ([[United Kingdom|UK]]) |
||
|- |
|- |
||
| bgcolor="#eeeeee" | Routes of administration |
| bgcolor="#eeeeee" | Routes of administration |
||
| Line 51: | Line 51: | ||
Nazitidine proved to be the last new histamine H<sub>2</sub>-receptor antagonists introduced prior to the advent of [[proton pump inhibitor]]s. |
Nazitidine proved to be the last new histamine H<sub>2</sub>-receptor antagonists introduced prior to the advent of [[proton pump inhibitor]]s. |
||
| ⚫ | |||
| ⚫ | |||
[[th:นิซาติดีน]] |
[[th:นิซาติดีน]] |
||
Revision as of 12:01, 20 March 2006
|
Molecular structure of nizatidine | |
| N-[2-(2-dimethylaminomethylthiazol- 4-ylmethylthio)ethyl]-N'-methyl- 2-nitrovinylidenediamine | |
| CAS number 66357-35-5 |
ATC code |
| Chemical formula | C12H21N5O2S2 |
| Molecular weight | 331.5 |
| Bioavailability | >70% |
| Metabolism | hepatic |
| Elimination half-life | 1-1.5 hours |
| Excretion | renal |
| Pregnancy category | B3 (Australia) |
| Legal status | Schedule 4 (Australia) POM (UK) |
| Routes of administration | oral |
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.
Clinical use
Main article: H2-receptor antagonist
Certain preparations of nizatadine are now available over the counter in various countries including the United States.
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine.
Nazitidine proved to be the last new histamine H2-receptor antagonists introduced prior to the advent of proton pump inhibitors.